Sartorius

Sartorius is one of the world's leading providers of laboratory and process technologies and equipment. Our innovative products and high-quality services help customers around the globe implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. Our key customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. Strongly rooted in the scientific and research communities and closely allied with customers and technology partners, the company is dedicated to its philosophy of "Turning science into solutions" every single day.

Florian Funck

CFO

Maurice Phelan

President, North America

19 past transactions

Virocell Biologics

Convertible Note in 2024
Virocell Biologics is a contract development and manufacturing organization that specializes in the production of viral vectors and gene-modified cells. The company focuses on facilitating the development of novel cell and gene therapies, allowing these innovations to progress into clinical trials. Virocell Biologics offers a platform designed to ensure a rapid, safe, and reliable transition from laboratory research to clinical application, thereby reducing risks and enhancing the value of emerging therapies. Through its services, Virocell Biologics supports medical researchers by providing the necessary gene-modified cells for their clinical studies.

TheWell Bioscience

Corporate Round in 2024
TheWell Bioscience is a biotechnology company that specializes in 3D cell culture technology aimed at enhancing life science research. The company has developed an innovative cell culture hydrogel system designed to facilitate drug screening, tissue engineering, and pre-clinical studies. By bridging the gap between traditional in vitro studies and in vivo models, TheWell Bioscience provides researchers with a robust platform for drug discovery and personalized medicine. This technology supports scientists in their efforts to conduct more accurate and relevant analyses, ultimately advancing the healthcare industry.

SPARTA Biodiscovery

Seed Round in 2023
SPARTA Biodiscovery offers Facilitating nanoformulations for upcoming therapies.

Polyplus-transfection

Acquisition in 2023
Polyplus-transfection SA is a biotechnology company that develops, markets and sells innovative solutions for the in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in Eastern France, Polyplus-transfection has been ISO 9001-certified since 2002 and supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network. Polyplus reagents are involved in a growing number of clinical trials worldwide. In addition, Polyplus-transfection holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery.

Albumedix

Acquisition in 2022
Albumedix is a biotechnology company based in Nottingham, England, that specializes in developing albumin-based drug enhancement technologies to create superior biopharmaceuticals. With a focus on improving therapies for serious diseases, the company partners with pharmaceutical organizations to deliver advanced drug and vaccine formulations. Its product offerings include drug stabilization, cell therapy formulation, and drug conjugates, which help clients in formulating effective treatments. With a dedicated team of over 80 professionals, Albumedix is recognized as a leader in the industry, contributing to both clinical and marketed drugs while remaining committed to enhancing patient quality of life through innovative albumin-enabled therapies.

Novasep - Chromatography Equipment

Acquisition in 2022
Novasep - Chromatography Equipment comprises resin-based batch and intensified chromatography systems, and focuses on low & high pressure for small and large molecules such as monoclonal antibodies, oligonucleotides, peptides and insulin.

ALS Automated Lab Solutions

Acquisition in 2021
ALS Automated Lab Solutions specializes in providing advanced laboratory services tailored for life science applications. Its flagship product, the ALS CellCelector, is an automated system designed for mammalian cell line generation. This innovative platform enables the scanning of cell culture plates to identify and select target cells or colonies with high precision. By integrating advanced robotic technology with sophisticated image processing software, the CellCelector offers exceptional image quality and real-time quality control during the picking process. The use of disposable tips eliminates the risk of cross-contamination, while the system's design ensures minimal maintenance requirements. Overall, ALS Automated Lab Solutions aims to enhance efficiency and accuracy in laboratory workflows, ultimately benefiting scientists in their research endeavors.

Xell

Acquisition in 2021
Xell is a partner for biotech and pharmaceutical companies, specializing in cell culture technology to enhance the production of biopharmaceuticals, diagnostic proteins, viral vectors, and vaccines. The company offers a diverse product portfolio that includes cell culture media, feeds, dietary supplements, and customized formulations tailored to meet the specific needs of its clients. With a team of experienced experts, Xell focuses on delivering efficient solutions for cell culture challenges, leveraging advanced analytical tools for the characterization of biological systems and pharmaceutical proteins. By collaborating closely with customers, Xell aims to optimize their bioprocesses and improve overall production capabilities in the healthcare sector.

CellGenix

Acquisition in 2021
They develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. Their products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. As an ATMP developer and manufacturer they gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background they understand the high requirements their customers face during product development and the regulatory approval process.

Biological Industries

Acquisition in 2019
Biological Industries is a manufacturer focused on developing life science research products, particularly in the areas of cell culture and molecular biology. The company specializes in creating cell culture media tailored for stem cell research and potential cell therapy applications. Its offerings include products for stem cell culture and differentiation, human cytogenetics, tissue culture, and custom cell media formulation. Additionally, Biological Industries provides services in contract manufacturing, mycoplasma detection and elimination, as well as cell proliferation and viability assessments. Furthermore, the company produces QF-PCR test kits, supporting academic institutions, biotechnology firms, and pharmaceutical companies with innovative solutions in the fields of cell therapy and molecular biology.

Danaher Life Science

Acquisition in 2019
Danaher Life Sciences provide scientists with meaningful research tools and services to gain a better understanding of biological and chemical matters. The combined efforts of Beckman Coulter Life Sciences, SCIEX, Molecular Devices, Pall, and Leica Microsystems work synergistically to provide increasingly sophisticated technologies designed to integrate across systems faster and with more accurate data.

ForteBio

Acquisition in 2019
ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

MKS Umetrics

Acquisition in 2017
Umetrics is a leading specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes.

Essen BioScience

Acquisition in 2017
Essen BioScience is a world leader in the field of cell-based in vitro assays and instrumentation. Our inventions have spanned nearly twenty years, and are recognized as “first in class” in several technology areas including optical cell-based screening (FLIPR, 1994), high through electrophysiology (IonWorks, 2002) and kinetic imaging (IncuCyte, 2006; IncuCyte ZOOM, 2012). To date, our inventions have accounted for nearly 1 billion dollars in worldwide sales.

ViroCyt

Acquisition in 2016
ViroCyt focuses on the commercialization of novel technologies that enable the rapid quantification of viruses. Our goal is to provide the tools that deliver meaningful improvements to mission-critical processes, such as vaccine manufacturing, protein expression, antiviral development, and other settings where viruses play a significant role. It was founded in 2012 and is based in Broomfield, Colorado.

kSep Systems

Acquisition in 2016
kSep Systems, LLC specializes in automated single-use bioprocessing solutions tailored for the biopharmaceutical industry, particularly in recombinant therapeutics, cell therapy, and vaccine manufacturing. The company's flagship technology, kSep, enables efficient harvesting of cells as either a product or by-product during the manufacturing process. This innovative system retains particles, such as cells or microcarriers, in a concentrated fluidized bed while maintaining a continuous flow of media or buffer. kSep Systems addresses the limitations of traditional centrifugation methods by providing fully automated, gentle processing environments that enhance the concentration, washing, and separation of cells, thereby ensuring high recovery rates. Founded in 2011 and headquartered in Morrisville, North Carolina, kSep Systems operates as a subsidiary of Sartorius Stedim Biotech S.A., building on its legacy as a former subsidiary of KBI Biopharma Inc.

TAP Biosystems

Acquisition in 2013
TAP Biosystems specialise in the design and manufacture of automated cell culture and fermentation systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.